Munir Pirmohamed
TitleCited byYear
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients
M Pirmohamed, S James, S Meakin, C Green, AK Scott, TJ Walley, ...
Bmj 329 (7456), 15-19, 2004
Estimation of the warfarin dose with clinical and pharmacogenetic data
International Warfarin Pharmacogenetics Consortium
New England Journal of Medicine 360 (8), 753-764, 2009
Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance
RA Sharma, SA Euden, SL Platton, DN Cooke, A Shafayat, HR Hewitt, ...
Clinical Cancer Research 10 (20), 6847-6854, 2004
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
AK Daly, PT Donaldson, P Bhatnagar, Y Shen, I Pe'er, A Floratos, MJ Daly, ...
Nature genetics 41 (7), 816, 2009
Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer
RA Sharma, HR McLelland, KA Hill, CR Ireson, SA Euden, MM Manson, ...
Clinical Cancer Research 7 (7), 1894-1900, 2001
HLA-A* 3101 and carbamazepine-induced hypersensitivity reactions in Europeans
M McCormack, A Alfirevic, S Bourgeois, JJ Farrell, D Kasperavičiūtė, ...
New England Journal of Medicine 364 (12), 1134-1143, 2011
Active transport of imatinib into and out of cells: implications for drug resistance
J Thomas, L Wang, RE Clark, M Pirmohamed
Blood 104 (12), 3739-3745, 2004
A randomized trial of genotype-guided dosing of warfarin
M Pirmohamed, G Burnside, N Eriksson, AL Jorgensen, CH Toh, ...
New England Journal of Medicine 369 (24), 2294-2303, 2013
Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes
EC Davies, CF Green, S Taylor, PR Williamson, DR Mottram, ...
PLoS one 4 (2), e4439, 2009
Adverse drug reactions
M Pirmohamed, AM Breckenridge, NR Kitteringham, BK Park
Bmj 316 (7140), 1295-1298, 1998
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing
JA Johnson, L Gong, M Whirl‐Carrillo, BF Gage, SA Scott, CM Stein, ...
Clinical Pharmacology & Therapeutics 90 (4), 625-629, 2011
Emergence and global spread of epidemic healthcare-associated Clostridium difficile
M He, F Miyajima, P Roberts, L Ellison, DJ Pickard, MJ Martin, TR Connor, ...
Nature genetics 45 (1), 109, 2013
Which drugs cause preventable admissions to hospital? A systematic review
RL Howard, AJ Avery, S Slavenburg, S Royal, G Pipe, P Lucassen, ...
British journal of clinical pharmacology 63 (2), 136-147, 2007
The role of metabolic activation in drug-induced hepatotoxicity
BK Park, NR Kitteringham, JL Maggs, M Pirmohamed, DP Williams
Annu. Rev. Pharmacol. Toxicol. 45, 177-202, 2005
Genetic susceptibility to adverse drug reactions
M Pirmohamed, BK Park
Trends in pharmacological sciences 22 (6), 298-305, 2001
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology
T Eschenhagen, T Force, MS Ewer, GW De Keulenaer, TM Suter, ...
European journal of heart failure 13 (1), 1-10, 2011
Pharmacogenetics of warfarin: current status and future challenges
M Wadelius, M Pirmohamed
The pharmacogenomics journal 7 (2), 99, 2007
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles
MI Lucena, M Molokhia, Y Shen, TJ Urban, GP Aithal, RJ Andrade, ...
Gastroenterology 141 (1), 338-347, 2011
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups
NA Limdi, M Wadelius, L Cavallari, N Eriksson, DC Crawford, MTM Lee, ...
Blood 115 (18), 3827-3834, 2010
Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective
BK Park, M Pirmohamed, NR Kitteringham
Chemical research in toxicology 11 (9), 969-988, 1998
The system can't perform the operation now. Try again later.
Articles 1–20